Hey Trotsky. The paid promotional services used by BOCX is important to spread the word. I suppose it does not help to have great results if no investors know about it. When they reported their data on breast, ovarian and stomach cancer in 2003 hardly anything happened to their stock price!! Small cap digest is read by approx. 750000 potential investors and it certainly had a positive effect on the pps. I am sure that investors, who were already in before the rise are happy they used paid promotion. A lot of good companies have in the past used similar services like Eresearch (ERES) and (HEB) etc.
Regarding your worries about when to sell, well that is something we all have in all stocks we buy, and I can not see this should be a specific BOCX problem. As I see it, the big gamble here is whether they succeed in making a licence agreement or not with a major pharma. If they do the stock price will do a similar thing to what it did recently. I think 150-200 mill. in market cap. should be reasonable, meaning a 10-15 times increase from current levels (current market cap is 15 mill). From there on the next big rise would probably be when they attain FDA approval.
I believe there is a good chance with the impressive data they have, to obtain such an agreement, but only future will tell.
Of course other cancer markers are being developed, but Biocurex's is the only one so far I have seen that is universal, ie. exists in all cancer forms and detectable with very high precision.
In the mean time we should see a reaktion to a BB listing, and when the independant date from Paris arrives.
Cheers, A340
News 
Market Data 
Discover 
AI
